

AD _____

Award Number: DAMD17-98-1-8321

TITLE: Viral Vectors Selective for Metastatic Breast Cancer Tumor Cells

PRINCIPAL INVESTIGATOR: William Folk, Ph.D.

CONTRACTING ORGANIZATION: University of Missouri
Columbia, Missouri 65211

REPORT DATE: November 2000

TYPE OF REPORT: Annual

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for public release
distribution unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

20010424 124

REPORT DOCUMENTATION PAGE

Form Approved
OMB No. 074-0188

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Budget, Paperwork Reduction Project (0704-0188), Washington, DC 20503

1. AGENCY USE ONLY (Leave blank)		2. REPORT DATE November 2000	3. REPORT TYPE AND DATES COVERED Annual (01 Oct 99 - 01 Oct 00)	
4. TITLE AND SUBTITLE Viral Vectors Selective for Metastatic Breast Cancer Tumor Cells			5. FUNDING NUMBERS DAMD17-98-1-8321	
6. AUTHOR(S) William Folk, Ph.D.				
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) University of Missouri Columbia, Missouri 65211 e-mail: Folk@missouri.edu			8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012			10. SPONSORING / MONITORING AGENCY REPORT NUMBER	
11. SUPPLEMENTARY NOTES				
12a. DISTRIBUTION / AVAILABILITY STATEMENT Approved for public release distribution unlimited				12b. DISTRIBUTION CODE
<input checked="" type="checkbox"/> 13. ABSTRACT (Maximum 200 Words) We are developing gene therapy vectors derived from purified polyomavirus capsid proteins and genes assembled into chromatin. We hope to achieve selective targeting of the vectors by expressing on their surface, domains that bind receptors present on the surface of cancer cells. During the past year we have modified the polyomavirus VP1 capsid protein to contain sequences derived from urokinase plasminogen activator (uPA) responsible for binding to the urokinase plasminogen activator receptor (uPAR). Also, as a control, we have modified the VP1 protein with the FLAG epitope. The insertions of the uPA sequences have occurred at surface-exposed loops in the VP1 protein, defined by x-ray crystallographic analysis. These modified VP1 proteins have been expressed in E.coli and in insect cells. Methods for their purification have been developed, and their capacity to assemble into virion-like particles (VLPs) assessed by electron microscopy. While we have been able to assemble wild type VP1 expressed in either E.coli or insect cells into VLPs, only the modified VP1s expressed in insect cells form VLPs. This next year we plan to incorporate into them the chromatin-assembled DNAs and to assess their uptake by cells.				
<input checked="" type="checkbox"/> 14. SUBJECT TERMS Breast Cancer, IDEA			15. NUMBER OF PAGES 8	
			16. PRICE CODE	
17. SECURITY CLASSIFICATION OF REPORT Unclassified	18. SECURITY CLASSIFICATION OF THIS PAGE Unclassified	19. SECURITY CLASSIFICATION OF ABSTRACT Unclassified	20. LIMITATION OF ABSTRACT Unlimited	

NSN 7540-01-280-5500

Standard Form 298 (Rev. 2-89)
Prescribed by ANSI Std. Z39-18
298-102

Table of Contents

Front Cover	1
SF298	2
	3
Table of Contents	4
Introduction	
Key Research Accomplishments — Reportable Outcomes	8

Viral Vectors Selective for Metastatic Breast Cancer Tumor Cells

Introduction: The most life-threatening aspect of cancer is its capacity to invade normal tissue and to establish new foci of tumor cells at distant sites. While there has been some progress in understanding some of the genetic and cellular mechanisms involved in the conversion of normal cells to metastatic tumor cells, little progress has been made in utilizing what has been learned of the molecular mechanisms of metastasis to reduce its morbidity and mortality. The objective of this work is to do that by developing novel gene therapy vectors selective for metastatic cells. Selectivity will rely upon metastatic cells expressing receptors to which the vectors can adsorb and upon the metastatic cells expressing signal transduction pathways which will activate vector gene expression.

Research Accomplished:

1. Construction of modified VP1 gene(s)

The polyomavirus major capsid protein VP1 will self-assemble to make virus-like particles (VLP) without involvement of other capsid proteins (Salunke DM. *et al.* 1986 Cell. 46(6): 895-904; An K *et al.*, 1999 J. Gen Virol. 80: 1009-16). VLP can package and transfer DNA into eukaryotic recipient cells. The relative simplicity of self-assembly makes polyomavirus an attractive candidate for a gene therapy vector.

VP1 is composed of 384 amino acids and its 3-dimensional structure has been reported (Soeda E *et al.* 1980). Four loops, BC, DE, EF and HI are exposed on the outside surface in capsomere structure and hence may not be involved in forming virus-like particles. We selected those 4 loops as target sites to insert foreign peptides.

Structure of polyoma VP1 protein and sites of foreign peptide insertion




It has been shown that amino acid sequence of 13-32 of uPA is responsible for its binding to uPAR (Appella *et al.* 1987). Consequently, we have chosen to insert residues 10-34 of uPA into the VP1 protein so that it might interact with the uPAR receptor. The amino acid sequence of the uPA peptide(10-34) inserted into the VP1 gene is:

N C D C L N G G T C V S N K Y F S N I H W C N C P
10 15 20 25 30 34

It is possible that the uPA peptide inserted into VP1 protein might undergo conformational changes so that its binding capacity is lost. In that case, there will no specific interactions between virus-like particle and cancer cells and hence, no specific targeting. In such an event, a peptide that has high affinity for uPAR might be a possible alternative to the uPA peptide. Goodson RJ *et al.*(1994) selected 15-mer peptides with high affinity for uPAR using random bacteriophage display. The selected peptides have two short conserved sequences, neither of which is found in uPA protein. One such peptide, present in clone 20, (AEPMPHSLNFSQYLWYT), showed a higher affinity for the uPA receptor than original uPA peptide. The IC_{50} of that peptide for the uPAR was 0.01uM while that of uPA[12-32 C19A] was 0.25 uM.

We also have inserted this 20 residue peptide into the loops of VP1. To help evaluate the effect of insert size on VP1 structure, a FLAG epitope was inserted in the HI loop of VP1. Self-assembly of VP1:FLAG protein will be compared with those of other proteins which containing uPA peptide or clone 20 peptide.




2. Expression and Purification of VP1 protein(s) in *E. coli*

To insert the uPA peptide or clone 20 peptide sequence into the VP1 gene, PCR-based cloning was employed and the modified genes sequenced. Modified VP1 genes made from PCR were cloned into the pET-15b vector and expression of protein was investigated in BL21 LysS cells. Protein expression was confirmed by SDS-PAGE and western-blot analysis using anti-VP1 antibody.

We have applied the method for purifying expressed VP1 protein developed by Leavitt A. *et al.* (1985), to purify modified VP1 proteins. The major purification steps are as follows:

Purification of wild type and Modified VP1 proteins

Culture of bacterial cells
 ↓
 Induction(0.2mM IPTG, 6hr at 28°C)
 ↓
 harvest and sonication(supernatant:①)
 ↓
 Polymyxin P precipitation(0.35% (w/v))
 ↓
 Extract w/ high salt & (NH₄)₂SO₄ precipitation
 ↓
 Resuspend pellet with buffer A(50mM NaCl)
 ↓
 DEAE column(flow through: ②)
 ↓
 Phosphocellulose column
 (elute with 1M NaCl: ③)
 Adopted from procedure by Leviatt *et al.* (8)
 Modified proteins can be purified by same procedure.



3. Self-assembly of VP1 protein(s) *in vitro*


Purified VP1 proteins undergo self-assembly in high ionic condition to make virus-like particles (VLPs). Once VLPs are formed, they can be stabilized in low ionic strength buffers (100mM NaCl) with calcium ions (Salunke DM *et al.* 1986). Wild type and modified VP1 proteins expressed in *E. coli* were incubated in buffer containing Tris 20 mM (pH = 7.3), ammonium sulfate (0.75 M), 5% glycerol and 1mM calcium chloride to allow self-assembly. Under transmission electron microscopy, assembled capsid-like particles look like native virus (Salunke DM *et al.* 1986, Forstova *et al.*, 1995).

We found with the *E.coli* expressed proteins, that only wild type VP1 protein self-assembles to make VLP, for the modified VP1 proteins undergo precipitation in the buffer and conditions used for self-assembly. To promote self-assembly of modified VP1 protein, various changes of assembly buffer were tried including addition of detergent, pH change (6.3-8.3) and concentration of calcium chloride. However none of these modifications were successful. Consequently, as an alternative, we turned to baculovirus expression of the VP1 proteins in insect cells, which have also been reported to support self-assembly of VP1 protein.

4. Cloning of wild type and modified VP1 gene(s) into baculovirus and protein expression:

Wild type and modified VP1 gene(s) were cloned into the pFastBac expression plasmid and transformed into DH10Bac competent cells containing Bacmid plasmid DNA. Recombinant bacmids containing wild type or modified VP1 gene(s) were purified and transfected into Hi-5 insect cells to obtain recombinant baculovirus. These were


amplified to obtain high titer virus stocks. To produce VLP, confluent monolayer of Hi-5 cells were infected with recombinant baculoviruses and incubated for 4 days. Protein production was evaluated by western blot analysis.




5. Purification of VLP and transmission electron microscopy

After harvesting the infected cells by low speed centrifugation, Hi-5 cells were disrupted by brief sonication and the lysate was centrifuged at 10,000g for 30 minutes, with the supernatant being saved. The pellet was re-extracted by sonication and centrifuged same as above. The supernatant was saved and combined with the original supernatant. VLPs were concentrated through 2ml of a 20% sucrose shelf and centrifuged at 35,000rpm for 120 minutes in a Beckman SW40 rotor. The pellet containing the partially purified VLPs was resuspended in small volume of buffer and layered on top of a preset cesium chloride gradient (1.35g/ml-1.23g/ml) and centrifuged at 33,000rpm for 15 hours in a SW40 rotor and then fractions were collected. The fraction containing VLP was dialyzed and used for transmission electron microscopy. Unlike the modified VP1 proteins produced in *E.coli*, modified VP1 proteins produced in insect cells could self-assemble to make VLPs.

Electron microscopy image of VLPs



VLPs made from insect cell expressed VP1



Native polyoma virus

Key research Accomplishments to date:

1. We have expressed and purified polyomavirus VP1 proteins containing inserts derived from sequences that bind uPAR.
2. We have assembled virus like particles (VLPs) from these modified proteins.

Reportable Outcomes:

1. Development of clones that express chimeric VP1 proteins.
2. Development of procedures for the purification and self-assembly of modified VP1 proteins
3. Progress toward completion of a PhD degree by Mr Young-Shin, graduate student.

Conclusion: We have essentially completed Technical Objectives 1 & 2 of the Statement of Work. This year we will focus upon Technical Objective #3. I am requesting a no-cost extension of the grant for one year to allow us to complete Technical Objective #4.

References

- An K, *et al* Use of the baculovirus system to assemble polyomavirus capsid-like particles with different polyomavirus structural proteins: analysis of the recombinant assembled capsid-like particles. *J Gen Virol*. 1999 Apr;80 (Pt 4):1009-16.
- Appella E, *et al*. The receptor-binding sequence of urokinase. A biological function for the growth-factor module of proteases. *J Biol Chem*. 1987 Apr 5;262(10):4437-40.
- Forstova J, *et al* . Polyoma virus pseudocapsids as efficient carriers of heterologous DNA into mammalian cells. *Hum Gene Ther*. 1995 Mar; 6(3):297-306.
- Funato T. *et al*. Gene delivery using adeno-associated (AAV) vectors *Nippon Rinsho*. 1998 Mar; 56(3):701-4
- Goodson RJ, High-affinity urokinase receptor antagonists identified with bacteriophage peptide display. *Proc Natl Acad Sci U S A*. 1994 Jul 19;91(15):7129-33.
- Leavitt AD, *et al*. Polyoma virus major capsid protein, VP1. Purification after high level expression in *Escherichia coli*. *J Biol Chem*. 1985 Oct 15; 260(23):12803-9.
- Salunke DM, *et al*. Self-assembly of purified polyomavirus capsid protein VP1. *Cell*. 1986 Sep 12;46(6):895-904.
- Soeda E, *et al*. Polyoma virus DNA: complete nucleotide sequence of the gene which codes for polyoma virus capsid protein VP1 and overlaps the VP2/VP3 genes. *J Virol*. 1980 Feb; 33(2):619-30.